In mouse models of NSCLC, cucurbitacin B effectively inhibits tumor growth and shows superior anti-tumor effects compared to standard treatments, underscoring its potential as a targeted therapy through the TLR4/NLRP3/GSDMD signaling axis [90]. This evidence concerns the gene TLR4 and neoplasm.